Outcome for children with group III rhabdomyosarcoma treated with or without radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 4, 2004, Pages 1208-1214

  Viswanathan, Akila N ^a   Grier, Holcombe E ^b   Litman, Heather J ^b,c   Perez Atayde, Antonio ^d   Tarbell, Nancy J ^e   Neuberg, Donna ^b   Shamberger, Robert C ^d   Marcus, Karen J ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chemotherapy; Pediatric; Radiotherapy; Rhabdomyosarcoma; Surgery

Indexed keywords

BRAIN; CHEMOTHERAPY; HISTOLOGY; PATIENT TREATMENT; SURGERY;

COMPLETE SURGICAL RESECTION (CSR); RELAPSE-FREE SURVIVAL;

RADIOTHERAPY;

CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RHABDOMYOSARCOMA; TREATMENT OUTCOME; TUMOR BIOPSY;

ADOLESCENT; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY DOSAGE; REMISSION INDUCTION; RHABDOMYOSARCOMA; TREATMENT FAILURE; TREATMENT OUTCOME; VINCRISTINE;

EID: 1542376207     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.08.027     Document Type: Article

References (21)

1. Wexler L., Crist W., Helman L. Rhabdomyosarcoma and the undifferentiated sarcomas. Pizzo P.A., Poplack D.G. Principles and practices of pediatric oncology. 4th ed. 2001;939-971 Lippincott, Williams & Wilkins, Philadelphia.
2. What are the key statistics about Rhabdomyosarcoma? http://health.yahoo. com/health/cancer_center/acs_crc/rhabdomyosarcoma.
3. Lawrence W., Gehan E.A., Hays D.M., et al. Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma A report from the Intergroup Rhabdomyosarcoma Study (IRS-II). J Clin Oncol. 5:1987;46-54.
4. Maurer H.M., Beltangady M., Gehan E.A., et al. The Intergroup Rhabdomyosarcoma Study-I A final report. Cancer. 61:1988;209-220.
5. Maurer H.M., Gehan E.A., Beltangady M., et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer. 71:1993;1904-1922.
6. Crist W., Gehan E.A., Ragab A.H., et al. The third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 13:1995;610-630.
7. Donaldson S.S., Meza J., Breneman J.C., et al. Results from the IRS-IV randomized trial of hyperfractionated radiation in children with rhabdomyosarcoma - A report from IRSG. Int J Radiat Oncol Biol Phys. 51:2001;718-728.
8. Cox D.R. The analysis of binary data. 1970;Metheun, London.
9. Cox D.R., Hinkley D.V. Theoretical statistics. 1974;Chapman and Hall, London.
10. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
11. Crist W., Garnsey L., Beltangady M., et al. Prognosis in children with rhabdomyosarcoma A report of the Intergroup Rhabdomyosarcoma Studies I and II. J Clin Oncol. 8:1990;443-452.
12. Sutow W.W., Sullivan M.P., Reid H.L., et al. Prognosis in childhood rhabdomyosarcoma. Cancer. 25:1970;1385-1390.
13. Tefft M., Lindberg R.D., Gehan E.A. Radiation therapy combined with systemic chemotherapy of rhabdomyosarcoma in children Local control in patients enrolled in the Intergroup Rhabdomyosarcoma Study. Natl Cancer Inst Monogr. 56:1981;75-81.
14. Gaiger A.M., Soule E.H., Newton W.A. Jr. Pathology of rhabdomyosarcoma Experience of the Intergroup Rhabdomyosarcoma Study, 1972-78. Natl Cancer Inst Monogr. 56:1981;19-27.
15. Tefft M, Wharam M, Gehan E. Local and regional control by radiation of rhabdomyosarcoma in IRS II. [Abstract] Int J Radiat Oncol Biol Phys 1998;15(Suppl. 1):159.
16. Tefft M., Wharam M., Ruymann F., et al. Radiotherapy (RT) for rhabdomyosarcoma (RMS) in children A report from the Intergroup Rhabdomyosarcoma Study #2 (IRS-2). Int J. Radiat Oncol Biol Phys. 10(Suppl. 2):1984;86.
17. Wolden S.L., Anderson J.R., Crist W.M., et al. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma A report from the Intergroup Rhabdomyosarcoma Studies I to III. J Clin Oncol. 17:1999;3468-3475.
18. Constine L.S., Marcus R.B., Halperin E.H. The future of therapy for childhood rhabdomyosarcoma Clues from molecular biology. Int J Radiat Oncol Biol Phys. 32:1995;1245-1249.
19. Rousseau P., Flamant F., Quintana E., et al. Primary chemotherapy in rhabdomyosarcomas and other malignant mesenchymal tumors of the orbit Results of the International Society of Pediatric Oncology MMT 84 study. J Clin Oncol. 12:1994;516-521.
20. Oberlin O., Rey A., Anderson J., et al. Treatment of orbital rhabdomyosarcoma Survival and late effects of treatment - Results of an international workshop. J Clin Oncol. 19:2001;197-204.
21. Flamant F., Rodary C., Rey A., et al. Treatment of non-metastatic rhabdomyosarcoma in childhood and adolescence - Results of the second study of the International Society of Pediatric Oncology MMT84. Eur J Cancer. 34:1998;1050-1062.